This cross-sectional study evaluates insurance and patient spending for the spinal muscular atrophy medications nusinersen, onasemnogene abeparvovec-xioi, and risdiplam from 2021 through 2022.
JAMA Pediatrics published a clinical update in Research Highlights on 13 Apr 2026.
The item focuses on Out-of-Pocket Cost of Gene Therapies Among Insured Patients.
Review the original article for the full source wording and details.